US EditionAn Experimental Treatment for an Early Blood Injury Has Generated a 100% Response According to the Results Presented at the Annual Meeting of the International Society for Mielom
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
An experimentally administered treatment in patients with advanced blood cancer demonstrated significant results in an intermediate phase clinical study, presented at the annual meeting of the International Myeloma Society (IMS), held between 17 and 20 September in Toronto, Canada.
Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) — Today, the Multiple Myeloma Research Foundation® (MMRF) announced that data generated from several MMRF initiatives were presented at the prestigious 22nd International Myeloma Society (IMS) Annual Meeting. The MMRF team presented five posters, while new findings from its Immune Atlas and CoMMpass℠ programs underpinned 18 additional presentations, […] The post Multiple Myeloma Research Foundation…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
